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Objective: To evaluate lung function and respiratory morbidity prospectively during the first year of life in 
patients with congenital diaphragmatic hernia (CDH) and to study the effect of extracorporeal membrane 
oxygenation therapy (ECMO).  
Design: Prospective longitudinal cohort study 
Setting: Outpatient clinic of a tertiary level pediatric hospital 
Patients: The cohort of 43 infants included 12 patients treated with ECMO. Evaluation was at 6 and 12 
months; 33 infants were evaluated at both time points.  
Interventions: None 
Measurements: Maximal expiratory flow at functional residual capacity (V’maxFRC) and functional residual 
capacity (FRCp) were measured with Masterscreen Babybody (Viasys). Z-scores were calculated for 
V’maxFRC.  
Main results: Mean V’maxFRC values at 6 and 12 months were significantly below the expected values 
(mean Z-scores -1.4 and -1.5, respectively) without a significant change between both time points. Values 
did not significantly differ between ECMO and non-ECMO-treated patients. FRCp values were generally 
high, 47% were above the suggested normal range, and did not change significantly over time. Mean 
FRCp values in ECMO patients were significantly higher than in non-ECMO patients (p=0.006). The 
difference (5.1 ml/kg ± 1.8 SE) did not change significantly between the two time points. Higher mean 
airway pressure and longer duration of ventilation were associated with higher FRCp. None of the 
perinatal characteristics was associated with V’maxFRC. Mean weight Z-scores were significantly below 
zero at both time points (p<0.001). Mean weight Z-scores in ECMO patients were lower than in non-
ECMO patients (p=0.046).  
Conclusions: Infants with CDH have decreased expiratory flows and increased functional residual 
capacity within the first year of life. ECMO-treated CDH patients may have more respiratory morbidity and 
concomitant growth impairment. Close follow-up beyond the neonatal period is therefore required. 
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Congenital diaphragmatic hernia (CDH) occurs in 1 in 3000 live births and accounts for 8% of all major 
congenital anomalies (1). Many patients show lung hypoplasia and pulmonary hypertension requiring 
ventilatory support of variable duration. Conventional management includes different forms of mechanical 
ventilation (SIMV, IPPV, high-frequency oscillatory ventilation (HFOV), with or without inhaled nitric 
oxide). Infants with severe respiratory failure and high mortality risk will receive extracorporeal membrane 
oxygenation (ECMO) therapy in specialized centers. ECMO provides a cardiopulmonary bypass using 
minimal ventilator settings, potentially avoiding ongoing lung damage. Surgical repair of the 
diaphragmatic defect is delayed until stabilization is achieved and cardio respiratory condition has been 
optimized (2). These strategies have raised survival rates of CDH patients to almost 80% (3-4). However, 
survivors have high risk of respiratory morbidity through different stages of life. For example, ventilator 
induced lung injury and high concentrations of oxygen predispose newborns to develop 
bronchopulmonary dysplasia (BPD) (5). 
Previous studies showed that ventilated CDH patients’ lung volume was reduced during the immediate 
perioperative period and that their respiratory system compliance was low (6-7). A retrospective study in 
infants with CDH showed abnormal lung function indices in the first 6 months, which gradually normalized 
by 24 months (8). Recently, our group reported significantly higher lung volumes in the first year in 
ECMO-treated CDH patients than in infants who received ECMO for meconium aspiration syndrome (9). 
Results of studies investigating pulmonary sequelae of non-ECMO patients in late childhood and 
adolescence were indicative of persistent airway obstruction and increased airway responsiveness (10-
12). 
We prospectively evaluated CDH patients’ lung function at 6 and 12 months of age and looked for a 
possible effect of ECMO treatment on respiratory morbidity. We also studied possible associations 





A prospective longitudinal follow-up was conducted in all surviving patients with CDH admitted to the 
intensive care unit of the Erasmus MC - Sophia Children’s Hospital between November 2004 and 
November 2008. (Flow chart, Figure 1). All patients were ventilated according to the principles of 
permissive hypercapnia and ventilatory support was provided either by conventional ventilation (Babylog 
8000, Dräger Medical, Lübeck, Germany) or high-frequency oscillatory ventilation (Sensormedics, 
Bilthoven, the Netherlands). All infants were treated according to a standardized treatment protocol (13). 
ECMO treatment was applied in case of reversible severe respiratory failure as described by Reiss et al 
(13). ECMO treatment always was of the veno-arterial type. Procedures and in- and exclusion criteria 
were described previously (9).  
We recorded gestational age, birth weight, sex, side of the diaphragmatic defect, lung-to-head ratio (if 
available in case of a prenatal diagnosis) (14), position of the liver (intrathoracic or intra-abdominal, if 
available in case of a prenatal diagnosis), place of birth (inborn or outborn), initial ventilation mode (HFOV 
or conventional ventilation) and type of repair (primary or patch). Furthermore we recorded several 
indicators of illness severity: SNAP-II score during the first 12 hours (15), use of inotropics, use and 
maximal dose of inhaled nitric oxide (iNO), use of sildenafil, ECMO treatment, highest mean airway 
pressure (MAP), and duration of ventilatory support and supplemental oxygen provision. The presence 
and severity of BPD were determined as described by Bancalari (16). 
The study was part of a follow-up programme for CDH patients in which lung function, growth and 
developmental parameters are regularly assessed until 18 years of age (17). The assessment protocol is 
the standard of care in the Netherlands. The Medical Ethical Review Board Erasmus MC stated that 
“Medical Research in Human Subjects Act (also known by its Dutch abbreviation "WMO”) does not apply 
to this research proposal, since subjects are not being submitted to any handling, nor are there rules of 
human behaviour being imposed”. Therefore IRB approval was waived. All parents were informed about 
the study and provided permission to use the data for research purposes. Lung function data were 




Lung function was measured at the ages of 6 and 12 months (corrected for prematurity), provided there 
were no signs of infection or acute respiratory symptoms. Patients were not mechanically ventilated and 
were independent of supplemental oxygen at the time of lung function measurement. Infants were 
sedated with chloral hydrate (50-75 mg/kg). Forced expiratory flow at FRCp (V’maxFRC), a measure of 
airway patency and compressibility, was determined by the end-tidal rapid thoracoabdominal 
compression technique (Masterscreen Babybody, Viasys, Hochberg, Germany). The mean V’maxFRC 
(ml/kg) of 3 to 5 technically acceptable measurements was calculated. All equipment and procedures 
complied with the guidelines of the ERS/ATS Task force on standards for infant respiratory testing (18). 
Regarding V’maxFRC, we used the reference values provided by Hoo and colleagues (19). Z-scores were 
calculated as the difference between observed and predicted value divided by the residual standard 
deviation from the reference values for V’maxFRC. Functional residual capacity (FRCp) was measured by 
whole body plethysmography (Masterscreen Babybody, Viasys, Hochberg, Germany). The mean FRCp 
(ml/kg) of 3 to 5 technically acceptable measurements was calculated. FRCp was expressed in ml/kg as 
suggested by Hülskamp et al (20). The normal range suggested by those authors was 13 to 26 ml/kg.  
VmaxFRC Z-scores and FRCp (ml/kg) were the primary outcome measures.  
 
Respiratory morbidity and physical growth  
The infants were physically examined at both follow-up visits. Examination included measurement of 
height and weight, pulmonary auscultation, and neurological examination. Respiratory rate (RR) was 
measured during lung function assessment. The following factors were recorded: supplemental oxygen 
provision, episodes of wheezing, number of respiratory tract infections (RTI), therapeutic and prophylactic 
courses of antibiotic treatment, and use of inhaled bronchodilators and corticosteroids.  
Dutch population data served as reference values for physical growth (21). Z-scores for weight and height 
were calculated using Growth Analyser version 3.5 (Dutch Growth Foundation). Z-scores < -1.96 (2.5
th
 
percentile of the reference population) were considered abnormally low; Z-scores > 1.96 (97.5
th
 percentile 
of the reference population) were considered abnormally high. Z-scores for patients treated with ECMO 
were calculated separately. 




Patient characteristics are presented as number of patients (percentage) or median (range). Univariate 
analyses were performed, using Chi-squared and Mann-Whitney U tests where appropriate, to evaluate 
differences between ECMO and non-ECMO patients.  Anthropometric and lung function data are 
presented as mean (SD).  
In this longitudinal study, the data are composed of repeated lung function measurements obtained in 
different individuals at two time points (six and twelve months of age). In the majority of patients, 
assessment at both time points was performed whereas in others only measurements at one time point 
were obtained. Since repeated measurements ANOVA allows for missing data at one time point, FRCp, 
V’maxFRC, VmaxFRC Z-scores and Z-scores for weight and length were evaluated longitudinally using 
repeated measurements ANOVA, a method which allows for missing data at one time point (22). 
Possible associations between clinical characteristics and lung function parameters were also analysed 
using ANOVA. For this purpose, highest MAP and the duration of ventilation were transformed 
logarithmically to reduce the effect of outlying observations. To evaluate a possible influence of ECMO 
treatment on FRCp, VmaxFRC Z-scores and Z-scores for weight and length, we specifically performed 
ANOVA analyses adjusting for ECMO treatment. Possible associations between clinical characteristics 
between ECMO treated and-non ECMO treated patients were also evaluated in an ANOVA adjusting for 
age (6 and 12 months).  
The significance level was set at p < 0.05. SPSS 17.0 (Chicago, Illinois) was used for the analyses.  
 
Results 
Between November 2004 and November 2008, 62 newborns with CDH had been admitted, of whom 48 
had survived (77%). Two were lost to follow-up and 3 were clinically unstable or needed supplemental 
oxygen at the time of lung function assessment. Thus, 43 infants with CDH were included (Figure 1). 
Thirty-three infants were measured both at 6 and 12 months of age. Reasons for not completing both 
measurements were being awake during one of the measurements (n= 4), loss to follow-up (n=1), 
recurrent RTI (n=1). Furthermore, 4 infants whose first measurement was performed with different 





Table 1. Baseline characteristics (n=43) 
Data from the total group (n=43) and the subgroups of ECMO-patients (n=12) and non-ECMO patients 
(n=31). P-values are given for differences between the ECMO and non-ECMO group. Data are 
demonstrated as number (%) or median (range).* 
Variables .Total (n=43) ECMO (n=12) Non-ECMO (n=31) p-value 
Males  30 (70) 10 (83) 20 (65) 0.290 
Left-sided defect 39 (91) 11 (92) 28 (90) 1.000 
Prenatal diagnosis 27 (63) 4 (33) 23 (74) 0.032 
Lung-to-head ratio  2 (0.9-3.5) 1.5 (1.3-2.4) 1.7 (0.9-3.5) 0.689 
Intrathoracic liver position  9 (21) 2 (17) 7 (23) 0.702 
Inborn  27 (63) 4 (33) 23 (74) 0.032 
Gestational age, weeks 38.7 (33.6-41.4) 39.2 (36.9-41.4)  38.4 (33.6-41) 0.022 
Birth weight, kilograms 3.0 (1.7-4.7) 3.0 (2.3-4.6) 3.0 (1.7-3.7) 0.524 
High risk (intubated ≤ 6 hrs after birth) 41 (95) 12 (100) 29 (94) 1.000 
SNAPP-II score 21 (0-52) 37 (12-52) 16 (0-41) 0.095 
Treatment with HFO ventilation 30 (75) 12 (100) 18 (58) 0.019 
Patch repair  28 (65) 9 (75) 19 (61) 0.719 
Treatment with iNO  24 (56) 12 (100) 12 (39) <0.001 
iNO maximum dose, ppm 20 (10-30) 20 (15-30) 20 (10-20) 0.574 
Maximal mean airway pressure,cm H2O 17 (10-29) 20 (17-29) 16 (10-20) <0.001 
Treatment with inotropics 39 (91) 12 (100) 27 (87) 0.563 
Treatment with sildenafil  7 (16) 6 (50) 1 (3) 0.001 
Bronchopulmonary dysplasia 16 (41) 7 (64) 9 (32) 0.150 
Duration of mechanical ventilation, days 10.3 (0.7-53.4) 22.2 (8.5-53.4) 8.1 (0.7-51.6) 0.002 
Duration of oxygen dependence, days  19.0 (3.0-141.3) 37.0 (9.6-141.3) 18.5 (3.0-104.5) 0.171 
 
*Data from the subgroups of infants measured at 6 months (n= 36) and at 12 months (n=40) did not differ 
significantly and are not shown. iNO: inhaled Nitric Oxide, ppm: parts per million. 
 
Lung function measurements  
The median postnatal age at the two lung function tests was 29.9 weeks (range 26.0-37.7, n=36) and 
56.1 weeks (range 49.3-66, n=40). The corresponding median age corrected for prematurity was 28.4 
weeks (range 25-37.7) and 54.4 weeks (range 50.1-66.9). Reliable V’maxFRC measurements were 
obtained in 29 patients at 6 months and in 38 patients at 12 months. Reliable FRCp measurements were 
obtained in 35 patients at 6 months and in 38 patients at 12 months. At 6 months 24 infants (73%) had a 
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RR ≥ 35 breaths/min, of whom 17 (52%) ≥ 40 breaths/min. At 12 months 18 infants (47%) had a RR of ≥ 
35 breaths/min, of whom 7 (18%) ≥ 40 breaths/min.  
Forty-seven percent of FRCp measurements were > 26 ml/kg (39% at 6 months and 55% at 12 months). 
The mean FRCp and mean Z-score of V’maxFRC did not change significantly over time. The results of the 
ANOVA analysis are presented in Table 2. 
 






P-value comparing the 2 
time points 








V’maxFRC (ml/sec) 108.0 (7.9) 153.9 (8.9) <0.001 
RR (breaths/min) 39.1 (1.2) 34.0 (1.2) <0.001 
 
Mean (SE) values from ANOVA are shown. FRCp: functional residual capacity. RR: respiratory rate. 
V’maxFRC (Z-score) 
†
: p<0.001below the reference value (Z=0).  
 
Associations between lung function parameters and clinical characteristics 
Overall, a longer duration of ventilation was associated with higher FRCp values at both 6 and 12 months 
(p=0.001). Doubling of the ventilation time resulted in a mean 1.9 ml/kg mean increase in FRCp. Higher 
MAP was also significantly associated with higher FRCp values at both time points (p=0.002). Furthermore, 
FRCp values were significantly higher (p=0.049) and V’maxFRC Z-scores were significantly lower (p=0.048) 
in patients who received treatment with iNO (p=0.049).  
Other significant associations between clinical characteristics and FRCp values or V’maxFRC Z-scores were 
not found.    
 
Lung function in ECMO patients 
A total of twelve patients received ECMO therapy (see table 1) for a median of 7.1 days (range 3-
12.1).The median day on which ECMO was started was the second day of life (range 1-4 days).  
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Table 1 lists clinical characteristics for both ECMO and non-ECMO patients. The former were less often 
prenatally diagnosed (p=0.032), less often inborn (p=0.032), had a higher median gestational age at birth 
(p=0.022), were more often treated with iNO (p<0.001) and sildenafil (p=0.001), had a higher median 
maximal mean airway pressure (p<0.001), were more often treated with HFO (p=0.019) and were 
ventilated for a longer time (p=0.002) than non-ECMO patients.  
At both time points, mean FRCp values differed significantly between ECMO- and non-ECMO-treated 
patients (p=0.006, Figure 2). This difference (5.1 ml/kg ± 1.8 SE) did not significantly change between the 
two time points (p=0.625). In ECMO patients, mean (SE) V’maxFRC Z-scores at 6 and 12 months were -
1.52 (0.31) and -1.54 (0.25) respectively. Mean (SE) V’maxFRC Z-scores at 6 and 12 months were -1.41 
(0.14) and -1.49 (0.15) in patients who did not receive ECMO therapy. These did not differ significantly 
(p=0.781).  
To further evaluate possible effects of clinical characteristics and ECMO therapy on FRCp values, these 
characteristics were entered in the ANOVA models together with the factor ECMO. When adjusted for 
duration of ventilation or highest mean airway pressure, the difference in FRCp values between ECMO 
and non-ECMO patients was not significant anymore (p=0.108 and p=0.369 respectively). No other 
significant associations between baseline characteristics and FRCp values were found when adjusted for 
ECMO.  
 
ECMO and BPD 
Sixteen patients developed BPD (41%, missing=4, see table 1). At both time points, BPD patients’ mean 
FRCp was significantly higher than that of the non-BPD patients (p<0.001, Figure 3). This difference (6.2 
ml/k kg ± 1.5 SE) did not significantly change between the two time points (p=0.585).  ANOVA did not 
reveal a significant effect of BPD on V’maxFRC Z-scores (p=0.159).  
Seven of the 11 ECMO-treated patients developed BPD (1 missing) versus 9 of the 28 non-ECMO 
patients (3 missing, p=0.15, see table 1). Simultaneous evaluation of BPD and ECMO resulted in a 
significant effect of BPD on FRCp (p=0.001, difference: 3.2 ml/kg lower in no BPD). The effect of ECMO 
was larger in this combined analysis (difference: 5.4 ml/kg lower in no ECMO) but did not reach statistical 
significance (p=0.066).  
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In Figure 4, individual FRCp measurements are shown for the 4 combinations of ECMO/non-ECMO and 
BPD/non-BPD. Data obtained at 6 and 12 months were clustered because there were no significant 
differences between the 2 time points.  
 
Respiratory morbidity and physical growth  
At 6 months, 4 patients (12%) had received at least one therapeutic course of antibiotics; the same was 
true for 7 patients (19%) at 12 months. One child used antibiotics daily for 12 months to prevent recurrent 
respiratory tract infections. Two (6%) and 5 (14%) patients used bronchodilators and/or inhaled 
corticosteroids at 6 and 12 months, respectively. At 6 and 12 months, 12 (28%) and 6 patients (14%) 
respectively had an abnormally low weight. Mean weight Z-scores were -1.01 (0.22) and -1.10 (0.18) at 6 
and 12 months, respectively, significantly below the norm (Z=0, p < 0.001 at both time points). At both 6 
and 12 months, weight Z-scores in ECMO-treated patients (6 months:-1.61 (0.37) and 12 months: -1.59 
(0.32)) were significantly lower than in patients without ECMO (6 months: -0.83 (0.22) and 12 months: -
0.82 (0.20), p=0.047). Mean height Z-scores were 0.02 (0.18) and 0.07 (0.16) at 6 and 12 months, 
respectively. Height Z-scores were not significantly different from normal at 6 and 12 months (p= 0.9 and 
p=0.6 respectively). At both time points, height Z-scores did not differ significantly between patients with 




This prospective longitudinal study revealed that FRCp in patients with CDH was generally above the 
expected range and did not change significantly from 6 to 12 months. Forced expiratory flows were below 
the expected value and also did not change. ECMO-treatment was associated with significantly higher 
FRCp. Presence of BPD, higher MAP and longer duration of ventilation were associated with higher FRCp. 
None of the perinatal characteristics was associated with V’maxFRC. 
Two studies by other groups reported reduced forced vital capacity and impaired maximal expiratory 
flows in neonates with CDH who were still on mechanical ventilation during lung function assessment (6-
7). In these studies, measurements were taken within the first weeks of life and the findings therefore 
cannot be compared to our findings in older and spontaneously breathing infants. A retrospective 
evaluation in 56 CDH patients showed that FRCp Z-scores, measured with the nitrogen washout 
technique, were initially below average but increased after the first 6 months of life; V’maxFRC was below 
average throughout the first year of life (8). A study using the sulphur hexafluoride wash-in/wash-out 
technique found similar FRCp levels in 13 CDH patients and in age-matched healthy controls (23). Earlier, 
our group found higher FRCp levels in ECMO-treated CDH patients than in infants who needed ECMO-
support for meconium aspiration syndrome (9). These findings on FRCp are in line with the present 
findings. 
In the present study, FRCp values were generally above the expected range. This is likely to be due to the 
lung hypoplasia that is inherent to CDH (24-27). Repair of CDH is usually followed by compensatory 
hyperinflation of the ipsilateral and/or the contralateral lung to fill the space previously occupied by 
abdominal organs (8). Helms and Stocks, however, found normal to low FRCp in infants aged up to 8 
weeks after operative repair of CDH (28). They argued that normal lung volume does not necessarily 
imply normal intrauterine lung development. Indeed, normal lung volume later in infancy (29) may be the 
result of alveolar distension and even of destructive emphysema of a hypoplastic lung (24, 30). Nagaya 
and co-workers, using computed tomography scans and perfusion scintigrams in infants following surgical 
repair of CDH and ECMO treatment, found ipsilateral lung volumes that were 61% of contralateral lung 
volumes at 3 months and had increased to 88% at 3 years of age (31). Perfusion of the affected side 
remained low, or decreased to below the initial value. These authors concluded that the ipsilateral lung 
apparently may have little ability to develop arterial branches and that enlargement of lung volume may 
depend on overexpansion or progressive emphysema, rather than on an increase in lung tissue (31). 
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Hayward and co-workers suggested that expansion of already existing alveoli and not an increase in the 
number of alveoli explained most of the lung growth in their CDH population 0.1-13 years(32). Thus, the 
normal, near-normal or elevated FRCp values in our study are more likely to reflect hyperinflation than 
true lung tissue growth. FRCp values did not increase from 6 to 12 months, so there seems to be no 
progressive hyperinflation. Indeed, studies in older children after repair of CDH showed mildly increased 
residual volume and mild airway obstruction (10-12). 
The question remains whether increased FRCp levels in CDH result from abnormal lung development or 
from lung damage due to barotrauma and hyperoxia. Most studies on lung function in BPD patients 
without CDH concern prematurely born neonates. As CDH patients are mainly born at term, findings are 
hard to compare. Studies on term born infants with BPD are scarce. However, Hofhuis and co-workers 
found that FRCp levels at 6 and 12 months in in ECMO-treated CDH patients were significantly higher 
than those in neonates treated with ECMO for meconium aspiration syndrome (MAS) (9). Fifteen of the 
25 MAS patients (60%) in that studied developed BPD (personal communication). This suggests that the 
elevated FRCp values in our population resulted from abnormal lung development in CDH patients rather 
than from the neonatal intensive care treatment. This assumption is supported by the study of 
Beardsmore and co-workers who found similar FRCp levels in term born neonates treated with ECMO or 
with conventional ventilation (33).  
It could be argued that plethysmography in CDH patients with or without BPD in the present study may 
not be suitable to evaluate alveolar functional recovery. On the other hand, gas dilution FRC 
measurements also has limitations, and underestimates lung volumes as gas diffusion is suboptimal in 
airways with an elevated resistance. Hence, we propose that follow-up should include both lung function 
studies and lung imaging to evaluate the evolution of lung volume in CDH patients. 
In the present study, FRCp in ECMO-treated patients was higher than in the other patients. We may 
speculate that ECMO treatment increases the chance of survival in case of CDH with more severe lung 
hypoplasia and/or persistent pulmonary hypertension, and consequently a higher respiratory morbidity 
and more hyperinflation of the lungs (9). Indeed, after failure of conventional ventilation, HFO ventilation 
was used more frequently in the ECMO treated group. Also, total ventilation time and MAP were 
significantly higher in the ECMO treated group. In the ECMO treated group, 64% developed BPD versus 
32% in the non-ECMO treated group and although this difference did not reach statistical significance, it 
indicates more severe respiratory problems which is associated with higher FRCp. A study by Bernbaum 
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et al. reported a 63% incidence of BPD at discharge in survivors of CDH who underwent ECMO-
procedure (34). This incidence is the same as we found in our study. Also ECMO-treated patients 
received more often iNO and sildenafil in order to reduce pulmonary hypertension. 
The decreased maximal expiratory flows in our study are in agreement with findings from similar studies 
in CDH patients (6-8, 35). Abnormal airway size or alveolar architecture may play a role here together 
with airway damage from mechanical ventilation. We found neither significant differences in forced 
expiratory flows between patients treated conservatively or with ECMO, nor between patients who did or 
did not develop BPD. Therefore, it seems that differences in FRCp cannot be explained by differences in 
airway obstruction only.  
Although 41% of the patients developed BPD, only few suffered from respiratory tract infections requiring 
antibiotic treatment. Only few patients had wheezing and/or dyspnea requiring inhaled medication. We 
speculate that an increased airflow obstruction is indicative of abnormal airway structure and fibrosis as a 
result of lung injury rather than of increased airway responsiveness. All patients showed impaired growth 
during the first year of life, especially the ECMO-treated patients with weight Z-scores below average.  
A potential limitation of our study was that we were not allowed to examine healthy controls, as sedation 
of healthy infants for research purposes is not permitted in the Netherlands. Therefore, we had to use 
reference values published by others. We expressed FRCp values in ml/kg. The earlier reference 
equations to compute FRCp into Z-scores are perhaps not entirely appropriate for data obtained with the 
newer equipment. We therefore expressed results as ml/kg, which is acceptable in the neonatal period, 
as the regression of FRCp on weight is relatively linear and passes close to the origin (36). Until new 
reference data are available, users of new equipment would do well to interpret results cautiously. The 
normal range of FRC, suggested by Hülskamp et al, is 13-26 ml/kg, mean 19.6, SD 3.4 (20). Regarding 
V’maxFRC, we used the references values provided by Hoo and colleagues. These reference values are 
based on a large representative population of healthy infants (19) and have been used by others using 
similar equipment as we did (37). Another limitation was the lack of well defined parameters to assess the 
severity of pulmonary hypertension and the effect on cardiac function by cardiac ultrasound 
retrospectively. A possible relation between lung function parameters in the first year of life and severity 
of pulmonary hypertension shortly after birth could therefore not be established. Also, we did not evaluate 
pulmonary hypertension and a possible effect on lung function by cardiac ultrasound during follow-up. 
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In summary, we found evidence of lung hyperinflation and impaired lung growth in CDH survivors after 
ECMO-treatment. Long-term monitoring of these patients’ lung function evolution is recommended.  
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Figure 1: Flowchart 
Figure 1. *2 patients were lost to follow up, 3 patients still had oxygen therapy at the time of lung function 
assessment and therefore measurements could not be performed 
CDH: congenital diaphragmatic hernia 
PPHN: therapy resistant persistent pulmonary hypertension of the neonate 
MCA: multiple congenital anomalies 
 
Figure 2 : FRCp at 6 and 12 months in ECMO and non-ECMO treated CDH patients 
FRCp (ml/kg) measurements in CDH patients who were treated with ECMO (2 panels left side; ECMO) 
and in those who were not treated with ECMO (2 panels right side; no ECMO) at the age of 6 and 12 
months. Bars denote mean values from repeated measurements ANOVA. Data shown at the bottom 
represent means with standard error (SE) between parentheses. Mean levels at both  6 and 12 months 
did not significantly differ between ECMO and non-ECMO treated patients (both p>0.60). 
 
Figure 3: FRCp at 6 and 12 months in CDH patients with and without BPD 
FRCp (ml/kg) measurements in CDH patients who developed BPD (2 panels left side; BPD) and those 
who did not develop BPD (2 panels right side; no BPD) at the age of 6 and 12 months. Bars denote mean 
values from repeated measurements ANOVA. Data shown at the bottom represent means with SE 
between parentheses. Mean levels at both 6 and 12 months did not significantly differ between patients 
with and without BPD (both p>0.30). 
 
Figure 4: FRCp measurements in four different groups of CDH patients 
FRCp (ml/kg) measurements of CDH at 6 and 12 months. Closed symbols represent ECMO-treated 
newborns; open symbols represent non-ECMO treated patients. BPD is indicated as circles; no-BPD as 
triangles. Thus, 4 different groups are shown. Bars denote mean values from repeated measurements 
ANOVA. Data shown at the bottom represent means with SE between parentheses.  
* mean level in this group significantly differed from that in the no ECMO/no BPD group (both p≤0.003). 
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